Graham Capital Management, L.P. Vertex Pharmaceuticals Inc Transaction History

Graham Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $216,075 - $236,422	530 Added 29.01%	2,357 $985,000
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $626,661 - $750,312	1,827 New	1,827 $743,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $359,696 - $402,585	1,144 New	1,144 $402,000
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $24,097 - $26,886	-88 Reduced 0.62%	14,195 $4.11 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $2.73 Million - $3.4 Million	11,624 Added 437.16%	14,283 $4.02 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $49,376 - $58,196	223 Added 9.15%	2,659 $693,000
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $431,196 - $544,324	2,436 New	2,436 $534,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.